KZR Share Price | Kezar Life Sciences, Inc. Stock Analysis & Recommendation

Q: How big is Kezar Life Sciences, Inc.?

Market Cap: As of Jun 18, Kezar Life Sciences, Inc. has a market capitalization of 29.88 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 0.00 million, while the sum of Net Profit amounts to -78.64 million.Balance Sheet Snapshot: As of Dec 24, the Shareholder's Funds are reported at 116.92 million, and the Total Assets stand at 144.68 million.

Q: What does Kezar Life Sciences, Inc. do?

Overview: Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025) Market cap: USD 29.88 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.99 Return on Equity: -74.87% Price to Book: 0.29Contact Details: Address: 4000 Shoreline Ct Ste 300, SOUTH SAN FRANCISCO CA: 94080-2005 Tel: ['1 650 8225600', '1 212 2130006'] Fax: 1 302 6365454 Website: http://kezarlifesciences.com/

Q: Is Kezar Life Sciences, Inc. technically bullish or bearish?

As of 2 June 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on both the weekly and monthly time frames, while the KST also reflects a mildly bullish stance in the same periods. However, the Bollinger Bands indicate a bearish trend on the weekly and a mildly bearish trend on the monthly. The daily moving averages are bearish, and Dow Theory shows a bearish signal on the monthly with no trend on the weekly. Overall, the mixed signals suggest a lack of strong bullish momentum, reinforcing the mildly bearish outlook.

Q: Is Kezar Life Sciences, Inc. overvalued or undervalued?

As of 12 November 2024, the valuation grade for Kezar Life Sciences, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently assessed as overvalued given its financial metrics, including a Price to Book Value of 0.31 and an EV to EBITDA ratio of 0.85. The negative ROE of -74.87% further underscores the challenges the company faces in generating returns for its shareholders.In comparison to peers, Kezar Life Sciences, Inc. shows a less favorable position relative to CARA Therapeutics, Inc., which has a P/E ratio of -6.235, and Kodiak Sciences, Inc., also marked as does not qualify with a P/E of -0.9925. The company's recent stock performance has been underwhelming, with a year-to-date return of -36.61%, contrasting sharply with the S&P 500's gain of 2.44% over the same period. Overall, the combination of poor financial ratios and relative underperformance suggests that Kezar Life Sciences, Inc. is overvalued in the current market landscape.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

26.86 k

Shareholding (Sep 2025)

FII

6.19%

Held by 28 FIIs

DII

76.94%

Held by 14 DIIs

Promoter

3.87%

How big is Kezar Life Sciences, Inc.?

22-Jun-2025

As of Jun 18, Kezar Life Sciences, Inc. has a market capitalization of 29.88 million, categorizing it as a Micro Cap company, with total assets of 144.68 million and shareholder's funds of 116.92 million. The company reported net sales of 0.00 million and a net profit of -78.64 million over the latest four quarters.

View full answer

What does Kezar Life Sciences, Inc. do?

22-Jun-2025

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for autoimmune disorders and cancer. It has a market cap of approximately $29.88 million and reported a net profit loss of $17 million as of March 2025.

View full answer

Who are in the management team of Kezar Life Sciences, Inc.?

22-Jun-2025

As of March 2022, the management team of Kezar Life Sciences, Inc. includes Dr. Jean-Pierre Sommadossi (Independent Chairman), Dr. Christopher Kirk (President and Chief Scientific Officer), and CEO John Fowler, along with several independent directors. They oversee the company's strategic direction and operations.

View full answer

Is Kezar Life Sciences, Inc. technically bullish or bearish?

25-Jun-2025

As of June 2, 2025, the market trend is mildly bearish, indicated by mixed signals from the MACD and KST showing mild bullishness, while Bollinger Bands and daily moving averages reflect bearish trends.

View full answer

Is Kezar Life Sciences, Inc. overvalued or undervalued?

25-Jun-2025

As of November 12, 2024, Kezar Life Sciences, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to poor financial metrics, including a negative ROE of -74.87% and a year-to-date stock performance of -36.61%, significantly underperforming the S&P 500.

View full answer

Compare Kezar Life Sciences, Inc. with Similar Stocks

C4 Therapeutics, Inc.Compugen Ltd.Carmell Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 45 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.97

Return on Equity

-74.38%

Price to Book

0.55

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-11 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

4.69%

6 Months

-13.24%

1 Year

-16.18%

2 Years

-75.24%

3 Years

-86.83%

4 Years

-89.37%

5 Years

-88.69%

Kezar Life Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-36.08%

EBIT to Interest (avg)

-56.87

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.99

Sales to Capital Employed (avg)

0.04

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

77.81%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.31

EV to EBIT

0.84

EV to EBITDA

0.85

EV to Capital Employed

-47.45

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-74.87%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 19 Schemes (13.01%)

Foreign Institutions

Held by 28 Foreign Institutions (6.19%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 18.25% vs 17.47% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.50",
          "val2": "-14.40",
          "chgp": "20.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.20",
          "val2": "-13.70",
          "chgp": "18.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.86% vs -49.41% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "7.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-88.10",
          "val2": "-104.20",
          "chgp": "15.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.60",
          "val2": "1.50",
          "chgp": "6.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.50",
          "val2": "-6.20",
          "chgp": "75.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-83.70",
          "val2": "-101.90",
          "chgp": "17.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-15,033.90%",
          "chgp": "1,503.39%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.50

-14.40

20.14%

Interest

0.00

0.30

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

-11.20

-13.70

18.25%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 18.25% vs 17.47% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

7.00

-100.00%

Operating Profit (PBDIT) excl Other Income

-88.10

-104.20

15.45%

Interest

1.60

1.50

6.67%

Exceptional Items

-1.50

-6.20

75.81%

Consolidate Net Profit

-83.70

-101.90

17.86%

Operating Profit Margin (Excl OI)

0.00%

-15,033.90%

1,503.39%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 17.86% vs -49.41% in Dec 2023

All Annual Results

Company CV

About Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc.

Pharmaceuticals & Biotechnology

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology, inflammation and immune-oncology.

Company Coordinates

Company Details

4000 Shoreline Ct Ste 300 , SOUTH SAN FRANCISCO CA : 94080-2005

Tel: 1 650 82256001 212 2130006

http://kezarlifesciences.com/

Registrar Details

Kezar Life Sciences, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Kezar Life Sciences, Inc.?

Watch in Real-Time

What does Kezar Life Sciences, Inc. do?

Who are in the management team of Kezar Life Sciences, Inc.?

Is Kezar Life Sciences, Inc. technically bullish or bearish?

Is Kezar Life Sciences, Inc. overvalued or undervalued?

Compare Kezar Life Sciences, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Kezar Life Sciences, Inc.

Company Coordinates